Company intelligence / Profile preview
EXUMA Biotech
West Palm Beach, Florida, USAexumabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
EXUMA Biotech has reported positive Phase 1 results for its autologous HER2-directed TMR CAR-T product CCT303–406 in metastatic HER2+ solid tumors. The therapy showed anti-tumor activity without dose-limiting toxicities or on-target/off-tumor toxicity. The company’s next-generation GCAR™ and SCL mRNA LNP technologies are advancing toward IND-enabling studies with non-human primate data expected in the first half of 2025.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Autologous CAR-T cell therapiesin vivo CAR-T therapiesgene vector delivery solutions
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on EXUMA Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXUMA Biotech.